L'intérêt à découvert pour Volatility Shares Trust 2x Bitcoin Strategy ETF donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Volatility Shares Trust 2x Bitcoin Strategy ETF. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Volatility Shares Trust 2x Bitcoin Strategy ETF (BATS:BITX), Rapport sur les intérêts à découvert

The Fund is an exchange-traded fund (ETF) that seeks to achieve its investment objective by investing its assets principally in cash-settled bitcoin futures contracts that trade only on an exchange registered with the Commodity Futures Trading Commission, which currently is the Chicago Mercantile Exchange (CME) (Bitcoin Futures Contracts), and cash, cash-like instruments or high-quality securities that serve as collateral to the Funds investments in Bitcoin Futures Contracts (Collateral Investments). The Fund also may invest in reverse repurchase agreement transactions and shares of other investment companies registered under the Investment Company Act of 1940 (Other Investment Companies).

2x Bitcoin Strategy ETF

Volatility Shares Trust 2x Bitcoin Strategy ETF

<p>Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $180.8, a high estimate of $210.00, and a low estimate of $145.00. This current average reflects an increase of 4.93% from the previous average price target of $172.30. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734732091_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Chart Industries's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ati Modak</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$201.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Gregory Lewis</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Pavel Molchanov</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Eric Stine</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$207.00</td>
<td>$199.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$146.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Chase Mulvehill</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$198.00</td>
<td>$199.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$146.00</td>
<td>$151.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Chart Industries. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Chart Industries compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Chart Industries's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Chart Industries's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GTLS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Chart Industries analyst ratings.</strong></a></p>
<h2>About Chart Industries</h2>
<p>Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company.</p>
<h3>Key Indicators: Chart Industries's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Chart Industries showcased positive performance, achieving a revenue growth rate of <strong>18.33%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Chart Industries's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>5.85%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Chart Industries's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.17%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Chart Industries's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.66%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.34</strong>, caution is advised due to increased financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

GTLS

Analyst Expectations For Chart Industries's Future

<p>Throughout the last three months, 15 analysts have evaluated Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $53.6, with a high estimate of $75.00 and a low estimate of $33.00. Marking an increase of 58.07%, the current average surpasses the previous average price target of $33.91. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734732084_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Doximity among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$49.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$33.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$45.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Doximity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Doximity compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Doximity's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into Doximity's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOCS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Doximity analyst ratings.</strong></a></p>
<h2>All You Need to Know About Doximity</h2>
<p>Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.</p>
<h3>Financial Insights: Doximity</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Doximity's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>20.44%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Doximity's net margin is impressive, surpassing industry averages. With a net margin of <strong>32.27%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Doximity's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.71%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Doximity's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>4.03%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DOCS

Forecasting The Future: 15 Analyst Projections For Doximity

<p>Throughout the last three months, 5 analysts have evaluated Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.8, along with a high estimate of $12.00 and a low estimate of $2.00. This current average has increased by 74.55% from the previous average price target of $2.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734732063_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Rigetti Computing. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Shannon</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$3.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rigetti Computing. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rigetti Computing compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Rigetti Computing's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Rigetti Computing's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RGTI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rigetti Computing analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Rigetti Computing</h2>
<p>Rigetti Computing Inc is engaged in the business of full-stack quantum computing. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, it derives a majority of its revenue from the United States.</p>
<h3>Rigetti Computing: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Rigetti Computing's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-23.41%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Rigetti Computing's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-623.76%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Rigetti Computing's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-12.11%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Rigetti Computing's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-9.28%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Rigetti Computing's debt-to-equity ratio is below the industry average at <strong>0.18</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RGTI

The Analyst Verdict: Rigetti Computing In The Eyes Of 5 Experts

<p>Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $5.55, along with a high estimate of $8.00 and a low estimate of $4.25. Witnessing a positive shift, the current average has risen by 6.73% from the previous average price target of $5.20.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734732051_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Lumen Technologies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bora Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$4.25</td>
<td>$4.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$6.50</td>
</tr>
<tr>
<td>Gregory Williams</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$4.50</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lumen Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Lumen Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Lumen Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Lumen Technologies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LUMN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lumen Technologies analyst ratings.</strong></a></p>
<h2>Discovering Lumen Technologies: A Closer Look</h2>
<p>With 450,000 route miles of fiber, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 in 2017 and divestiture of much of its incumbent local exchange carrier, or ILEC, business in 2022 has shifted the company's operations away from its legacy consumer business and toward enterprises (now about 75% of revenue). Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.</p>
<h3>Lumen Technologies: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Challenges:</strong> Lumen Technologies's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-11.54%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> Lumen Technologies's net margin excels beyond industry benchmarks, reaching <strong>-4.59%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Lumen Technologies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-36.63%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Lumen Technologies's ROA excels beyond industry benchmarks, reaching <strong>-0.44%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>55.03</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LUMN

What 5 Analyst Ratings Have To Say About Lumen Technologies

<p>Analysts' ratings for Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) over the last quarter vary from bullish to bearish, as provided by 26 analysts.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">10</td>
<td align="right">12</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">9</td>
<td align="right">12</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Marvell Tech and provided 12-month price targets. The average target is $118.88, accompanied by a high estimate of $140.00 and a low estimate of $91.00. This current average reflects an increase of 18.74% from the previous average price target of $100.12. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734732043_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Marvell Tech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Toshiya Hari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$132.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Rick Schafer</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$102.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$127.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Rick Schafer</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Hold</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Buy</td>
<td>$91.00</td>
<td>$91.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Marvell Tech. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Marvell Tech compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Marvell Tech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Marvell Tech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MRVL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Marvell Tech analyst ratings.</strong></a></p>
<h2>About Marvell Tech</h2>
<p>Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.</p>
<h3>Understanding the Numbers: Marvell Tech's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Marvell Tech showcased positive performance, achieving a revenue growth rate of <strong>6.87%</strong> as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-44.61%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-4.9%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-3.38%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.32</strong>, Marvell Tech adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MRVL

Beyond The Numbers: 26 Analysts Discuss Marvell Tech Stock

<p>Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $24.92, with a high estimate of $28.00 and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 11.15% increase from the previous average price target of $22.42.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734732034_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Blue Owl Cap. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$26.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Blue Owl Cap. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Blue Owl Cap compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Blue Owl Cap's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Blue Owl Cap's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OWL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Blue Owl Cap analyst ratings.</strong></a></p>
<h2>Get to Know Blue Owl Cap Better</h2>
<p>Blue Owl Capital Inc is an alternative asset management firm. The Company deploys private capital across Credit, GP Strategic Capital, and Real Estate platforms on behalf of institutional and private wealth clients. The Company conducts its operations through Blue Owl Capital Holdings LP ("Blue Owl Holdings") and Blue Owl Capital Carry LP ("Blue Owl Carry"). Its investor base includes a diversified mix of institutional investors, including public and private pension funds, endowments, foundations, family offices, private banks, high-net-worth individuals, asset managers, and insurance companies. The Company generates substantially all of its revenues in the United states.</p>
<h3>Blue Owl Cap's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Blue Owl Cap's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>39.85%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Blue Owl Cap's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>4.96%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Blue Owl Cap's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.59%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Blue Owl Cap's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.29%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Blue Owl Cap's debt-to-equity ratio surpasses industry norms, standing at <strong>1.45</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Blue Owl Cap In The Eyes Of 13 Experts

<p>Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 5 years by 11.03% on an annualized basis producing an average annual return of 24.01%. Currently, Novo Nordisk has a market capitalization of $377.67 billion. </p>
<p><strong>Buying $100 In NVO:</strong> If an investor had bought $100 of NVO stock 5 years ago, it would be worth <strong>$294.83</strong> today based on a price of $85.03 for NVO at the time of writing.</p>
<h3>Novo Nordisk's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734732019_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

<p>Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) has outperformed the market over the past 5 years by 2.55% on an annualized basis producing an average annual return of 15.52%. Currently, Nucor has a market capitalization of $28.02 billion. </p>
<p><strong>Buying $100 In NUE:</strong> If an investor had bought $100 of NUE stock 5 years ago, it would be worth <strong>$205.35</strong> today based on a price of $116.85 for NUE at the time of writing.</p>
<h3>Nucor's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734731107_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Nucor Stock In The Last 5 Years

<p>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.13) by 53.85 percent. This is a 60 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $1.91 million which beat the analyst consensus estimate of $1.72 million by 11.16 percent. This is a 27.49 percent decrease over sales of $2.64 million the same period last year.</p>


Earnings

XELB

Xcel Brands Q3 Adj $(0.06) Beats $(0.13) Estimate, Sales $1.91M Beat $1.72M Estimate

<p><strong>Xcel Brands</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) announced its Q3 earnings on Friday, December 20, 2024 at 04:30 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Xcel Brands beat estimated earnings by 54.0%, reporting an EPS of $-0.06 versus an estimate of $-0.13.</p>
<p>Revenue was down $725 thousand from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.07, leading to a 2.0% drop share price change the next day.</p>
<p>Here's a look at Xcel Brands's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.08</td>
<td>-0.18</td>
<td>-0.25</td>
<td>-0.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.01</td>
<td>-0.09</td>
<td>-0.24</td>
<td>-0.15</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>3.62M</td>
<td>2.20M</td>
<td>2.46M</td>
<td>2.80M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.95M</td>
<td>2.18M</td>
<td>2.29M</td>
<td>2.64M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Xcel Brands <a href="https://www.benzinga.com/quote/XELB/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Xcel Brands Earnings Report: Q3 Overview

LXRX

Lexicon Receives Complete Response Letter for Zynquista; Says This Expected Communication From The FDA Aligns With Previously Disclosed Strategic Decision To Discontinue Launch Preparations For Zynquista And Focus Solely On Its Clinical Development Pipeline

<p>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) reported quarterly losses of $(0.12) per share. This is a 25 percent increase over losses of $(0.16) per share from the same period last year. The company reported $4.47 million in sales this quarter. This is a 131.04 percent increase over sales of $1.94 million the same period last year.</p>


ILAG

Intelligent Living H1 EPS $(0.12) Up From $(0.16) YoY, Sales $4.47M Up From $1.94M YoY

<p><i><strong>Common Stock Will Begin Trading on a Split-Adjusted Basis on January 2, 2025</strong></i></p>
<p><strong>AtlasClear Holdings, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NYSE">ATCH</a>) ("AtlasClear Holdings" or the "Company") today announces that it intends to effect a 1-for-60 reverse stock split of its issued and outstanding shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split will become effective on December 31, 2024 (the "Effective Time") upon filing with the Delaware Secretary of State of an amendment to the Company's amended and restated certificate of incorporation (the "Charter"), and the Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on January 2, 2025. The Company's common stock will continue to trade on NYSE American LLC under the symbol "ATCH." The new CUSIP number for the common stock following the Reverse Stock Split will be 128745 205.</p>


Stock Split

ATCH

AtlasClear Holdings Announces 1-For-60 Reverse Stock Split, Common Stock Is Expected To Begin Trading On A Split-Adjusted Basis When The Market Opens On January 2, 2025

<p>The Tesla Model Y electric vehicle from <strong>Tesla Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) might not win title of Europe's bestselling vehicle for a second straight year, ending a short reign <a href="https://www.benzinga.com/electric-vehicles">for electric vehicles.</a></p>
<p><strong>What Happened: </strong>The Model Y broke records for <a href="https://www.benzinga.com/news/earnings/24/01/36768363/tesla-q4-earnings-highlights-revenue-miss-eps-miss-model-y-a-global-bestseller-next-gen-vehicle-upd">electric vehicles in 2023</a> and became the first EV to be the bestselling car globally for a full year. In Europe, it was the bestseller for 2023.</p>
<p>While the Model Y was Europe's <a href="https://www.benzinga.com/news/23/11/35969553/tesla-model-y-is-likely-bestselling-vehicle-in-europe-for-2023-the-record-breaking-numbers-why-its-i">top seller in 2023,</a> a repeat now appears unlikely.</p>
<p>According to <a href="https://www.autonews.com/retail/sales/ane-europe-top50-november-2024/#:~:text=The%20Tesla%20Model%20Y%20will,as%20Europe's%20top%2Dselling%20car.">data </a>from Automotive News Europe, the Model Y now ranks behind the Dacia Sandero, an internal combustion engine hatchback from French company <strong>Renault</strong>.</p>
<p>The data, shared by <a href="https://electrek.co/2024/12/19/tesla-model-y-likely-to-lose-its-crown-as-top-selling-car-in-europe-to-dacia-sandero/">Electrek</a>, shows that the Model Y ranks sixth through the month of November. </p>
<p>The Sandero led the way in November with 21,506 vehicles sold, with the Volkswagen Tiguan second at 18,618.</p>
<p>Year-to-date, the Model Y has 181,781 units sold in Europe, which ranks around 65,000 units behind the Dacia Sandero.</p>
<p>Tesla is offering several incentives through the end of year that could push the vehicle higher up the list, including a year of free charging at Tesla Supercharger locations to anyone who buys a Model Y before the end of the calendar year.</p>
<p>The BYD Song from <strong>BYD Co</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) is mentioned as a top performer for the year with sales up 42% year-over-year.</p>
<p><strong>Are you buying when the CEOs of the Magnificent 7 are selling?</strong></p>
<ul>
<li><strong>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></strong></li>
</ul>
<p><strong>Why It's Important</strong>: With a price point of $13,051, the Dacia Sandero is more appealing to many consumers in Europe looking for a less expensive new car and not willing to spend a higher amount to get an electric vehicle.</p>
<p>Tesla taking the top spot in Europe in 2023 was a great storyline for electric vehicles, but could be hard to replicate without cheaper EV models hitting the country. The Model Y refresh named Juniper and likely coming in 2025, could see Model Y figures get a boost worldwide in 2025.</p>
<p><strong>TSLA Price Action: </strong>Tesla stock was down 3% to $421.06 on Friday versus a 52-week trading range of $138.80 to $488.54. Tesla stock is up 70% year-to-date in 2024.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/education/24/10/41166723/how-many-evs-has-tesla-delivered-produced-each-quarter-a-look-at-the-results-since-2019">How Many EVs Has Tesla Delivered, Produced Each Quarter? A Look At The Results Since 2019</a></strong></li>
</ul>
<p><em>Photo: Dacia Sandero courtesy of Wikimedia Commons</em></p>


BYDDY

TSLA

Tesla Model Y Could Lose Bestselling Title In Europe To This Non-EV Car

Legal

QCOM

U.S. Judge Asks Arm And Qualcomm To Mediate After Mistrial, Says Neither Side Has Clear Victory If Case Is Tried Again

FDA Approves Eli Lilly's Zepbound For Moderate-to-Severe Obstructive Sleep Apnea In Adults With Obesity

Offerings

Wendy's Co Files For Mixed Shelf Offering; Size Not Disclosed

Management

ALVR

Allovir Says Diana Brainard Steps Down As CEO; Appointed Vikas Sinha As Company's CEO And Principal Executive Officer

<p>On December 20, 2024, the U.S. Food and Drug Administration approved ALYFTREK&#x2122; (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis in people 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive to ALYFTREK.</p>
<p><br />&nbsp;</p>
<p>We have established a wholesale acquisition cost for ALYFTREK in the United States of $370,269 on an annual basis ($28,404 per 28-day pack).</p>


VRTX

Vertex Pharmaceuticals Establishes Wholesale Acquisition Cost For Alyftrek In U.S. Of $370,269 On Annual Basis ($28,404 Per 28-day Pack)

Psyence Biomedical Files Prospectus Relates To Potential Offer, Sale, From Time To Time 10.9M Common Shares By Selling Securityholders

BITX: Rate Cuts Could Disappoint BTC Bulls

Bitcoin: Not Yet Ready To Launch The Breakout Rally (Rating Upgrade)

Gold and Bitcoin will benefit from a "debasement trade" caused by geopolitical tensions - analyst

2x Bitcoin Strategy ETF: A Sophisticated Tool

Is gold a better investment hedge than crypto? – SA Sentiment Survey

Bitcoin tops the $97,000 level: A closer look at financial conditions

SA Sentiment: Should the U.S. create a Strategic Bitcoin Reserve?

This is the level Bitcoin would have to reach under Trump to match Biden and his prior term

This is the level Bitcoin would have to reach under Trump to match Biden and his own prior term

Here's what Seeking Alpha analysts are saying as Bitcoin trades above $100K

AETH

ARKA

ARKB

ARKC

ARKW

ARKY

BETE

BETH

BITB

BITC

BITF

BITI

BITO

BITQ

BITS

BITU

BITW

BITX

BKKT

BLKC

BRRR

BTCO

BTCW

BTOP

CLSK

COIN

DEFI

EETH

ETHT

EZBC

FBTC

GBTC

GDXJ

HIVE

HODL

HOOD

IBIT

MARA

MSTR

NUGT

RIOT

SATO

SBIT

SPBC

STCE

WGMI

Comments

Volatility Shares Trust 2x Bitcoin Strategy ETF

Intérêt court

Volatility Shares Trust 2x Bitcoin Strategy ETF (BATS:BITX), Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL